Patients with atrial fibrillation (AF) and coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) represent a population at increased risk of thromboembolism and bleeding. Such patients may receive antithrombotic therapy based on low-quality evidence. The purpose of this study is to understand the care gaps between consensus guideline recommendations and current practice for optimal antiplatelet therapy and oral anticoagulation (OAC) in this patient population. A national, multi-centre anonymous survey was conducted with physicians involved in the care of patients with non-valvular AF and CAD, undergoing PCI. Surveys were completed both in continuing medical education seminars and web-based online. A total of 66 physicians completed the survey. The majority were interventional cardiologists/fellows (68%), followed by general cardiologists/residents (17%) and general internists (11%). 80% of the participants indicated the 2016 Focused Update of the Canadian Cardiovascular Society (CCS) guidelines as their most common resource; however, 39% disagreed and 6% strongly disagreed that CCS guidelines provided clear recommendations. Stroke and bleeding risk scores such as CHADS2 (67%) and HASBLED (73%) were most commonly used. Most participants preferred a direct oral anticoagulant with concomitant antiplatelet therapy (59%), and a small number preferred warfarin (8%). CCS guidelines continue to be the main resource for appropriate antiplatelet and OAC therapy for Canadian physicians. However, translation of CCS guidelines into clinical practice is a challenge as this survey indicates that treatment decisions widely vary.View Large Image Figure ViewerDownload Hi-res image Download (PPT)
Read full abstract